Review Article| Volume 5, ISSUE 1, P41-50, November 2022

High-Grade B-cell Lymphomas


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Advances in Molecular Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Swerdlow S.
        • Campo E.
        • Harris N.
        • et al.
        WHO classification of tumours of haematopoietic and lymphoid tissues.
        IARC Press, Lyon, France2017
        • Alaggio R.
        • Amador C.
        • Anagnostopoulos I.
        • et al.
        The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
        Leukemia. 2022; 36: 1720-1748
        • Campo E.
        • Jaffe E.S.
        • Cook J.R.
        • et al.
        The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
        Blood. 2022; 140: 1229-1253
        • Ennishi D.
        • Jiang A.
        • Boyle M.
        • et al.
        Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
        J Clin Oncol Off J Am Soc Clin Oncol. 2019; 37: 190-201
        • Li S.
        • Desai P.
        • Lin P.
        • et al.
        MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
        Histopathology. 2016; 68: 1090-1098
        • Pillai R.K.
        • Sathanoori M.
        • Van Oss S.B.
        • Swerdlow S.H.
        Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
        Am. J. Surg. Pathol. 2013; 37: 323-332
        • Rosenwald A.
        • et al.
        Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
        J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2019; 37: 3359-3368
        • Ye Q.
        • et al.
        Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
        Oncotarget. 2016; 7: 2401-2416
        • Li S.
        • Lin P.
        • Medeiros L.J.
        Advances in pathological understanding of high-grade B cell lymphomas.
        Expert Rev Hematol. 2018; 11: 637-648
        • Haralambieva E.
        • Boerma E.J.
        • van Imhoff G.W.
        • et al.
        Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma.
        Am J Surg Pathol. 2005; 29: 1086-1094
        • Swerdlow S.H.
        Diagnosis of “double hit” diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
        Hematol Am Soc Hematol Educ Program. 2014; 2014: 90-99
        • Zhang J.
        • et al.
        High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.
        Am. J. Surg. Pathol. 2020; 44: 1602-1611
        • Scott D.W.
        • et al.
        High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
        Blood. 2018; 131: 2060-2064
        • Johnson N.A.
        • Slack G.W.
        • Savage K.J.
        • et al.
        Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
        J Clin Oncol. 2012; 30: 3452-3459
        • Oki Y.
        • Noorani M.
        • Lin P.
        • et al.
        Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
        Br J Haematol. 2014; 166: 891-901
        • Künstner A.
        • Witte H.M.
        • Riedl J.
        • et al.
        Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing.
        Haematologica. 2021; 18
        • Wang W.
        • Hu S.
        • Lu X.
        • et al.
        Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
        Am J Surg Pathol. 2015; 39: 1132-1139
        • Landsburg D.J.
        • Falkiewicz M.K.
        • Maly J.
        • et al.
        Outcomes of patients with double-hit lymphoma who achieve first complete remission.
        J Clin Oncol Off J Am Soc Clin Oncol. 2017; 35: 2260-2267
        • Aukema S.M.
        • Siebert R.
        • Schuuring E.
        • et al.
        Double-hit B-cell lymphomas.
        Blood. 2011; 117: 2319-2331
        • Evrard S.M.
        • Péricart S.
        • Grand D.
        • et al.
        Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
        Haematologica. 2019; 104: e154-e157
        • Riedell P.A.
        • Smith S.M.
        Double hit and double expressors in lymphoma: Definition and treatment.
        Cancer. 2018; 124: 4622-4632
        • Reagan P.M.
        • Davies A.
        Current treatment of double hit and double expressor lymphoma.
        Hematol Am Soc Hematol Educ Program. 2017; 2017: 295-297
        • Wagener R.
        • et al.
        IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.
        Blood. 2018; 132: 2280-2285
        • Kim H.
        • Kim H.J.
        • Kim S.H.
        Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.
        Ann Lab Med. 2020; 40: 361-369
        • Kanagal-Shamanna R.
        • Medeiros L.J.
        • Lu G.
        • et al.
        High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis.
        Histopathology. 2012; 61: 945-954
        • Chong L.C.
        • Ben-Neriah S.
        • Slack G.W.
        • et al.
        High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.
        Blood Adv. 2018; 2: 2755-2765
        • Copie-Bergman C.
        • Cuillière-Dartigues P.
        • Baia M.
        • et al.
        MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
        Blood. 2015; 126: 2466-2474
        • McPhail E.D.
        • et al.
        Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.
        Haematologica. 2018; 103: 1899-1907
        • Karube K.
        • Enjuanes A.
        • Dlouhy I.
        • et al.
        Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
        Leukemia. 2018; 32: 675-684
        • Gebauer N.
        • Bernard V.
        • Thorns C.
        • et al.
        Oncogenic MYD88 mutations are rare events in double-hit B-cell lymphomas.
        Acta Haematol. 2015; 133: 113-115
        • Gebauer N.
        • Bernard V.
        • Gebauer W.
        • et al.
        TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.
        Leuk Lymphoma. 2015; 56: 179-185
        • Hilton L.K.
        • Tang J.
        • Ben-Neriah S.
        • et al.
        The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.
        Blood. 2019; 134: 1528-1532
        • Cucco F.
        • Barrans S.
        • Sha C.
        • et al.
        Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.
        Leukemia. 2020; 34: 1329-1341
        • Li J.
        • Liu X.
        • Yao Z.
        • et al.
        High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases.
        Cancer Manag Res. 2020; 12: 1903-1912
        • Baryakh E.A.
        • Misyurina A.E.
        • Kovrigina A.M.
        • et al.
        [Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma].
        Ter Arkh. 2015; 87: 77-85
        • Hans C.P.
        • Weisenburger D.D.
        • Greiner T.C.
        • et al.
        Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
        Blood. 2004; 103: 275-282
        • Hüttl K.S.
        • Staiger A.M.
        • Richter J.
        • et al.
        The “Burkitt-like” immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.
        Virchows Arch Int J Pathol. 2021; 479: 575-583
        • Bhavsar S.
        • Liu Y.-C.
        • Gibson S.E.
        • Moore E.M.
        • Swerdlow S.H.
        Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.
        Am. J. Surg. Pathol. 2022; 46: 71-82
        • Khanlari M.
        • et al.
        Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.
        Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc. 2022; 35: 419-426
        • Perry A.M.
        • Crockett D.
        • Dave B.J.
        • et al.
        B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases.
        Br J Haematol. 2013; 162: 40-49
        • Grygalewicz B.
        • Woroniecka R.
        • Rymkiewicz G.
        • et al.
        The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.
        Am J Clin Pathol. 2018; 149: 17-28
        • Gonzalez-Farre B.
        • Ramis-Zaldivar J.E.
        • Salmeron-Villalobos J.
        • et al.
        Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.
        Haematologica. 2019; 104: 1822-1829
        • Salaverria I.
        • Martin-Guerrero I.
        • Wagener R.
        • et al.
        A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.
        Blood. 2014; 123: 1187-1198
        • Ferreiro J.F.
        • Morscio J.
        • Dierickx D.
        • et al.
        Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern.
        Haematologica. 2015; 100: e275-e279
        • Gebauer N.
        • et al.
        Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma.
        Blood Adv. 2021; 5: 5220-5225
        • Horn H.
        • et al.
        A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas.
        Am. J. Surg. Pathol. 2021; 45: 356-364
        • Au-Yeung R.K.H.
        • et al.
        Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.
        Br. J. Haematol. 2020; 190: 753-763
        • Grygalewicz B.
        • Woroniecka R.
        • Rymkiewicz G.
        • et al.
        The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.
        Am J Clin Pathol. 2017; 149: 17-28
        • Pienkowska-Grela B.
        • Rymkiewicz G.
        • Grygalewicz B.
        • et al.
        Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement.
        Med Oncol Northwood Lond Engl. 2011; 28: 1589-1595
        • Havelange V.
        • Ameye G.
        • Théate I.
        • et al.
        The peculiar 11qgain/ loss aberration reported in a subset of MYCnegative high-grade B-cell lymphomas can also occur in a MYC-rearranged lymphoma.
        Cancer Genet. 2016; 209: 117-118
        • Rymkiewicz G.
        • Grygalewicz B.
        • Chechlinska M.
        • et al.
        A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration.
        Mod Pathol. 2018; 31: 732-743
        • Bouska A.
        • McKeithan T.W.
        • Deffenbacher K.E.
        • et al.
        Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma.
        Blood. 2014; 123: 1681-1690
        • Zajdel M.
        • Rymkiewicz G.
        • Chechlinska M.
        • et al.
        miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
        Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015; 36: 5377-5388
        • Wagener R.
        • Seufert J.
        • Raimondi F.
        • et al.
        The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
        Blood. 2019; 133: 962-966
        • King R.L.
        • McPhail E.D.
        • Meyer R.G.
        • et al.
        False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms.
        Haematologica. 2019; 104: e248-e251
        • Wierda W.G.
        • Rawstron A.
        • Cymbalista F.
        • et al.
        Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
        Leukemia. 2021; 35: 3059-3072
        • Galimberti S.
        • Genuardi E.
        • Mazziotta F.
        • et al.
        The Minimal Residual Disease in Non-Hodgkin’s Lymphomas: From the Laboratory to the Clinical Practice.
        Front Oncol. 2019; 9: 528
        • Chiappella A.
        • Crombie J.
        • Guidetti A.
        • et al.
        Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?.
        HemaSphere. 2019; 3: e284